医療倫理の進歩
オープンアクセス

概要

How to Connect Biomarkers with Imaging in Prostate Cancer?

Alessandro Sciarra, Beatrice Sciarra, Paolo Casale, Alessandro Gentilucci, Susanna Cattarino, Gianna Mariotti, Marco Frisenda, Giulio Bevilacqua, Stefano Salciccia

Due to the clinical heterogeneity of Prostate Cancer (PC) present in clinical practice, the analysis of the metabolic profile of PC samples could offer relevant information. Compared with genomics or proteomics, metabolomics better reflects changes in phenotype and functional aspects. Metabolomic studies can be related to imaging; in particular Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) have evolved as the most common techniques.

A relevant advantage using radiomics and artificial intelligence algorithms is the possibility to limit the discrepancies between different readers. This advantage could be particularly relevant in the use of multiparametric Magnetic Resonance (mMR) that is considered as a reader-dependent technique in qualitative evaluation. The association of genomic alteration with Multiparametric Magnetic Resonance results are likely to have a prognostic significance in PC the differential expression of genomic markers in MR-detected and undetectable lesions have been evaluated, in particular the association of Multiparametric Magnetic Resonance evaluation with the PTEN expression.